Palisade Bio (NASDAQ:PALI) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of Palisade Bio (NASDAQ:PALI – Free Report) from a sell rating to a strong sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

PALI has been the subject of a number of other reports. Oppenheimer restated an “outperform” rating on shares of Palisade Bio in a report on Wednesday, October 21st. HC Wainwright dropped their price target on shares of Palisade Bio to $5.00 and set a “buy” rating for the company in a research report on Wednesday, November 11th. Raymond James Financial initiated coverage on shares of Palisade Bio in a research note on Thursday, October 8th. They set an “outperform” rating and a $6.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Monday, October 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Palisade Bio currently has a consensus rating of “Buy” and an average price target of $9.00.

Get Our Latest Research Report on Palisade Bio

Palisade Bio Trading Down 8.0%

Shares of NASDAQ:PALI opened at $1.03 on Friday. The firm has a market cap of $184.66 million, a price-to-earnings ratio of -2.15 and a beta of 1.61. The stock’s 50-day moving average price is $1.46 and its two-hundred day moving average price is $1.81. Palisade Bio has a 12-month low of $1.01 and a 12-month high of $2.85.

Palisade Bio (NASDAQ:PALI – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). As a group, research analysts forecast that Palisade Bio will post -0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Palisade Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new position in shares of Palisade Bio in the 2nd quarter worth about $22,394,000. BlackRock Inc. acquired a new position in shares of Palisade Bio in the 2nd quarter valued at about $21,813,000. Soleus Capital Management L.P. lifted its stake in shares of Palisade Bio by 14.8% in the 3rd quarter. Soleus Capital Management L.P. now owns 14,996,154 shares of the company’s stock valued at $20,245,000 after purchasing an additional 1,932,467 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Palisade Bio by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 10,689,452 shares of the company’s stock worth $18,760,000 after purchasing an additional 149,118 shares during the period. Finally, Octagon Capital Advisors LP grew its holdings in shares of Palisade Bio by 7.4% during the 1st quarter. Octagon Capital Advisors LP now owns 10,276,317 shares of the company’s stock worth $17,984,000 after purchasing an additional 708,419 shares during the period. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio Company Profile

(Get Free Report)

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.

Recommended Stories

Analyst Recommendations for Palisade Bio (NASDAQ:PALI)

Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.